Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunocompromised patients. We hypothesized that simultaneous inhibition of biosynthesis of ergosterol in the fungal cell membrane and (1→3)-β-d-glucan in the cell wall, respectively, by the antifungal triazole isavuconazole (ISA) and the echinocandin micafungin (MFG) may result in improved outcomes in experimental IPA in persistently neutropenic rabbits. Treatments included ISA at 20 mg/kg of body weight/day (ISA20), 40 mg/kg/day (ISA40), and 60 mg/kg/day (ISA60); MFG at 2 mg/kg/day (MFG2); combinations of ISA20 and MFG2, ISA40 and MFG2, and ISA60 and MFG2; and no treatment (untreated controls [UC]). The galactomannan index (GMI) and (1→3)-β-d-glucan levels in serum were measured. The residual fungal burden (number of CFU per gram) was significantly reduced in ISA20-, ISA40-, ISA60-, ISA20-MFG2-, ISA40-MFG2-, and ISA60-MFG2-treated rabbits compared with that in MFG2-treated or UC rabbits ( < 0.01). Measures of organism-mediated pulmonary injury, lung weights, and pulmonary infarct score were lower in ISA40-MFG2-treated rabbits than in rabbits treated with ISA40 or MFG2 alone ( < 0.01). Survival was prolonged in ISA40-MFG2-treated rabbits in comparison to those treated with ISA40 or MFG2 alone ( < 0.01). These outcome variables correlated directly with significant declines in GMI and serum (1→3)-β-d-glucan levels during therapy. The GMI correlated with measures of organism-mediated pulmonary injury, lung weights ( = 0.764; < 0.001), and pulmonary infarct score ( = 0.911; < 0.001). In summary, rabbits receiving combination therapy with isavuconazole and micafungin demonstrated a significant dose-dependent reduction in the residual fungal burden, decreased pulmonary injury, prolonged survival, a lower GMI, and lower serum (1→3)-β-d-glucan levels in comparison to rabbits receiving isavuconazole or micafungin as a single agent.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571280 | PMC |
http://dx.doi.org/10.1128/AAC.00305-17 | DOI Listing |
J Pharm Biomed Anal
January 2025
Department of Pharmacology, Montpellier University Hospital, Avenue du Doyen Gaston Giraud, Montpellier 34090, France; Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), INSERM, University Montpellier, Montpellier 34090, France. Electronic address:
Ther Adv Infect Dis
October 2024
Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA.
JAC Antimicrob Resist
August 2024
Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Objectives: This study aimed to investigate the prevalence and characteristics of clinical and environmental isolates in Taiwan.
Methods: isolates obtained from patients at three hospitals and from 530 soil samples across Taiwan were screened. , confirmed by calmodulin sequencing, was subjected to antifungal susceptibility testing and analyses.
J Oncol Pharm Pract
August 2024
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Introduction: Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are commonly used in AML and are known to interact with anti-cancer drugs such as midostaurin through the CYP3A pathway. However, there are no midostaurin related dose modifications recommended with strong CYP3A inhibitors.
View Article and Find Full Text PDFHeliyon
June 2024
Department of Biological Sciences, University of Arkansas, Fayetteville, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!